Sign in Subscribe

Archive

A collection of 943 issues

Latest

Early-Onset CRC Shows Distinct Mutation Profile in Meta-Analysis of 154,982 Patients

Skip to content The CRC Digest ◇ RESEARCH Early-Onset CRC Shows Distinct Mutation Profile in Meta-Analysis of 154,982 Patients A systematic review found that colorectal cancer diagnosed before age 50 has higher frequencies of TP53 and SMAD4 mutations and lower frequencies of APC, KRAS, and BRAF mutations compared to late-onset

CRC Research Update — October 15, 2026

Today's colorectal cancer research highlights

KRAS and BRAF mutations drive distinct chromatin and transcriptional programs

Skip to content The CRC Digest KRAS and BRAF mutations drive distinct chromatin and transcriptional programs Isogenic cell models revealed that RAS pathway mutations reconfigure chromatin accessibility and modulate WNT signaling, with elevated TCF7L2 expression in BRAF-mutant tumors independently predicting worse overall survival. (Cell Commun Signal) This content is informational

Nomogram predicts survival in early-onset colorectal cancer using routine lab markers

Skip to content The CRC Digest Nomogram predicts survival in early-onset colorectal cancer using routine lab markers A prognostic model incorporating T/N stage, tumor markers, and systemic immune-inflammation index achieved 3-year survival prediction AUCs of 0.897 in training and 0.861 in external validation cohorts of 410 patients

FGFR inhibition enhances immune checkpoint blockade in preclinical models

Skip to content The CRC Digest ◇ RESEARCH FGFR inhibition enhances immune checkpoint blockade in preclinical models Combining FGFR pathway inhibition with PD-1 blockade reduced T cell exhaustion and promoted antitumor macrophage activity in microsatellite stable colorectal cancer models, with TCGA data showing high FGFR3 expression correlates with worse prognosis. (BMC

Survey finds low awareness of early-onset colorectal cancer among young adults

Skip to content The CRC Digest ♥ LIVING WITH CRC Survey finds low awareness of early-onset colorectal cancer among young adults A survey of 1,000 people aged 20-44 found only 24% were aware of early-onset colorectal cancer, 29% had not heard of any symptoms, and female respondents felt less comfortable

ctDNA-guided chemotherapy strategy misses primary endpoint but reduces neurotoxicity

Skip to content The CRC Digest ◆ TRIAL DATA ctDNA-guided chemotherapy strategy misses primary endpoint but reduces neurotoxicity The phase 2 PEGASUS trial in 135 patients with high-risk stage II/III colon cancer used serial ctDNA testing to guide treatment intensity; 3-year disease-free survival was 58.4% in ctDNA-positive patients versus

Fruquintinib plus TAS-102 shows activity in heavily pretreated metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Fruquintinib plus TAS-102 shows activity in heavily pretreated metastatic colorectal cancer A phase II trial of 50 patients who had failed at least two prior therapies found median progression-free survival of 6.07 months and overall survival of 14.10 months, with

CRC Research Update — October 14, 2026

Today's colorectal cancer research highlights

Surgically treated early-onset rectal neuroendocrine neoplasms increased from 234 to 778 cases annually

Skip to content The CRC Digest Surgically treated early-onset rectal neuroendocrine neoplasms increased from 234 to 778 cases annually A National Cancer Database analysis of 7,285 patients under 50 who underwent surgery for rectal neuroendocrine neoplasms found that annual cases increased from 234 in 2004 to 778 in 2023,